Following a government-wide hiring freeze and staff reductions affecting nearly 19% of its workforce, the FDA faces a deepening morale crisis amidst increasing political pressures and administrative cuts. Experienced employees are exiting in large numbers, impairing the agency’s ability to conduct high-quality product reviews and inspections, raising concerns about regulatory bottlenecks and decision-making in key areas like drug approvals and facility oversight.